CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment

Journal of Immunology

Volumn 162, Issue 8, 1999, Pages 4983-4990

  Zheng, Xin Xiao ^a   Markees, Thomas G ^c   Hancock, Wayne W ^d   Li, Yongsheng ^a   Greiner, Dale L ^c   Li, Xian Chan ^a   Mordes, John P ^c   Sayegh, Mohammed H ^b   Rossini, Aldo A ^c   Strom, Terry B ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; INTERLEUKIN 4; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MALE; MOUSE; NONHUMAN; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; T LYMPHOCYTE; TRANSFUSION; TRANSPLANTATION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; BLOOD TRANSFUSION; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; COMBINED MODALITY THERAPY; IMMUNE TOLERANCE; IMMUNOCONJUGATES; INTERLEUKIN-4; ISLETS OF LANGERHANS TRANSPLANTATION; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; TISSUE DONORS;

EID: 0004880266     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ogura, K., P. I. Terasaki, C. Johnson, R. Mendez, J. T. Rosenthal, R. Ettenger, D. C. Martin, E. Dainko, L. Cohen, and T. Mackett. 1993. The significance of a positive flow cylometry crossmatch test in primary kidney transplantation. Transplantation 56:294.
2. Roy-Chaudhury, P., P. W. Nickerson, R. C. Manfro, X. X. Zheng, J. Steiger, Y. S. Li, and T. B. Strom. 1997. CTLA4Ig attenuates accelerated rejection (presensitization) in the mouse islet allograft model. Transplantation 64:172.
3. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:121.
4. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90:6586.
5. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
6. Foy, T. M., A. Aruffo, J. Bajorath, J. E. Buhlmann, and R. J. Noelle. 1996. Immune regulation by CD40 and its ligand gp39. Annu. Rev. Immunol. 14:591.
7. Durie, F. H., T. M. Foy, and R. J. Noelle. 1994. The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease. Res. Immunol. 145:200.
8. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.
9. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, G. Laszlo, et al. 1993. Murine B7-2, an alternative CTLA4 counter-receptor that costimulation T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
10. Steurer, W., P. W. Nickerson, A. W. Steele, J. Steiger, X. X. Zheng, and T. B. Strom. 1995. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes grafts tolerance. J. Immunol. 155:1165.
11. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257:789.
12. Larsen, C. P., D. Z. Alexander, D. Hollenbaugh, E. T. Elwood, S. C. Ritchie, A. Aruffo, R. Hendrix, and T. C. Pearson. 1996. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 61:4.
13. Sayegh, M. H., and L. A. Turka. 1998. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338:1813.
14. Parker, D. C., D. L. Greiner, N. E. Phillips, M. C. Appel, A. W. Steele, F. H. Durie, R. J. Noelle, J. P. Mordes, and A. A. Rossini. 1995. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92:9560.
15. Kirk, A. D., D. M. Harlan, N. N. Armstrong, T. A. Davis, Y. Dong, G. S. Gray, X. Hong, D. Thomas, J. H. J. Fechner, and S. J. Knechtle. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94:8789.
16. Sayegh, M. H., X. G. Zheng, C. Magee, W. W. Hancock, and L. A. Turka. 1997. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 64:1646.
17. Hancock, W. W., M. H. Sayegh, X. G. Zheng, R. Peach, P. S. Linsley, and L. A. Turka. 1996. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 93:13967.
18. + T cells, interferon-γ. and CTLA4. J. Clin. Invest. 101:2446.
19. Elwood, E. T., C. P. Larsen, H. R. Cho, M. Corbascio, S. C. Ritchie, D. Z. Alexander, C. Tucker-Burden, P. S. Linsley, A. Aruffo, D. Hollenbaugh, et al. 1998. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 65:1422.
20. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fetal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541.
21. Walunas, T. L., D. J. Lenschow, G. Y. Bakker, P. S. Linsley, C. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
22. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompsom, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985.
23. Perez, V. L., L. V. Parijs, A. Biuckans, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vitro requires CTLA-4 engagement. Immunity 6:411.
24. Lin, H., J. C. Rathmell, G. S. Gray, C. B. Thompson, J. M. Leiden, and M. L. Alegre. 1998. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allograft in CD28-deficient mice: CTLA4 can function independently to CD28. J. Exp. Med. 188:199.
25. Zheng, X. X., M. H. Sayegh, X. G. Zheng, P. S. Linsley, R. Peach, F. Borriello, T. S. Strom, A. H. Sharpe, and L. A. Turka. 1997. The role of donor and recipient B7-1 (CD80) in allograft rejection. J. Immunol. 159:1167.
26. + T cell regulation during the induction phase of the response. Eur. J. Immunol. 25:2643.
27. Lin, Y., M. Vandeputte, and M. Waer. 1997. Factor involved in rejection of concordant xenografts in complement-deficient rats. Transplantation 63:1705.
28. Zheng, X. X., A. D. Schachter, L. Vasconcellos, J. Strehlau, Y. Tian, M. Shapiro, W. Harmon, and T. B. Strom. 1998. Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. Transplantation 65:1512.
29. Strehlau, J., M. Pavlakis, M. Lipman, M. Shapiro, L. Vasconcellos, W. Harmon, and T. B. Strom. 1997. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc. Natl. Acad. Sci. USA 94:695.
30. Sayegh, M. H., E. Akalin, W. W. Hancock, M. E. Russell, C. B. Carpenter, P. S. Linsley, and L. A. Turka. 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181: 1869.
31. Hurwitz, A. A., T. F. Yu, D. R. Leach, and J. P. Allison. 1998. CTLA-4 blockade synergized with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95:10067.